Literature DB >> 23461569

Susceptibility to repeated, low-dose, rectal SHIVSF162P3 challenge is independent of TRIM5 genotype in rhesus macaques.

Katherine Butler1, Jennifer S Morgan, Debra L Hanson, Debra Adams, J Gerardo Garcia-Lerma, Walid Heneine, Dennis Ellenberger, R Michael Hendry, Janet McNicholl, Welkin E Johnson, Ellen N Kersh.   

Abstract

Infections following repeated, low-dose (RLD), mucal S(H)IV exposures of macaques are used to model sexual HIV exposures for biomedical prevention testing. Different susceptibilities among animals can complicate study designs. In rhesus macaques, TRIM5 alleles Q, CypA, and TFP are resistance factors for infection with some S(H)IV strains, but not for SIVmac239 due to its capsid properties. SIVmac239-derived SHIVSF162P3 has been demonstrated to reproducibly infect mucosally in vaginal and rectal RLD models. To further test the suitability of SHIVSF162P3 for RLD models, we studied the influence of the TRIM5 genotype on susceptibility to rectal RLD infection and on plasma viremia by analyzing 43 male Indian rhesus macaques from control arms of completed studies. The median number of exposures required for infection was three (Q/Q, n=4) (TRIM5 alleles, number of macaques, respectively), four (Q/CypA, n=7), three (TFP/Q, n=15), three (TFP/TFP, n=15), and two (TFP/CypA, n=2); TRIM5(CypA/CypA) was not represented in our study. Median peak viremia (log10 viral copies/ml) in infected animals was 7.4 (Q/Q, n=4), 7.2 (Q/CypA, n=6), 7.3 (TFP/Q, n=13), 7.1 (TFP/TFP, n=15), and 6.5 (TFP/CypA; n=2). Neither susceptibility nor peak viremia was significantly different (log rank test, Kruskal-Wallis test, respectively). Rhesus macaques' susceptibility to RLD SHIVSF162P3 is independent of the TRIM5 TFP, CypA, and Q alleles, with the limitation that the power to detect any impact of CypA/CypA and TFP/CypA genotypes was nonexistent or low, due to absence or infrequency, respectively. The finding that TRIM5 alleles do not restrict mucosal infection or ensuing replication rates suggests that SHIVSF162P3 is indeed suitable for RLD experimentation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23461569      PMCID: PMC3685693          DOI: 10.1089/aid.2012.0383

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  24 in total

Review 1.  Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses.

Authors:  Frank Kirchhoff
Journal:  Cell Host Microbe       Date:  2010-07-22       Impact factor: 21.023

2.  Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor.

Authors:  Matthew Stremlau; Michel Perron; Mark Lee; Yuan Li; Byeongwoon Song; Hassan Javanbakht; Felipe Diaz-Griffero; Donovan J Anderson; Wesley I Sundquist; Joseph Sodroski
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-15       Impact factor: 11.205

3.  Repeated rectal SHIVSF162P3 exposures do not consistently induce sustained T cell responses prior to systemic infection in the repeat-low dose preclinical macaque model.

Authors:  Ellen N Kersh; Wei Luo; Debra R Adams; Priya Srinivasan; James M Smith; Nattawan Promadej-Lanier; Dennis Ellenberger; J Gerardo Garcia-Lerma; Salvatore Butera; Ron Otten
Journal:  AIDS Res Hum Retroviruses       Date:  2009-09       Impact factor: 2.205

4.  The TRIM5{alpha} genotype of rhesus macaques affects acquisition of simian immunodeficiency virus SIVsmE660 infection after repeated limiting-dose intrarectal challenge.

Authors:  Matthew R Reynolds; Jonah B Sacha; Andrea M Weiler; Gretta J Borchardt; Chrystal E Glidden; Neil C Sheppard; Francesca A Norante; Philip A Castrovinci; Jacqueline J Harris; Henry T Robertson; Thomas C Friedrich; Adrian B McDermott; Nancy A Wilson; David B Allison; Wayne C Koff; Welkin E Johnson; David I Watkins
Journal:  J Virol       Date:  2011-07-06       Impact factor: 5.103

5.  Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges.

Authors:  Shambavi Subbarao; Ronald A Otten; Artur Ramos; Caryn Kim; Eddie Jackson; Michael Monsour; Debra R Adams; Sheila Bashirian; Jeffrey Johnson; Vincent Soriano; Ana Rendon; Michael G Hudgens; Salvatore Butera; Robert Janssen; Lynn Paxton; Alan E Greenberg; Thomas M Folks
Journal:  J Infect Dis       Date:  2006-08-29       Impact factor: 5.226

6.  Variable prevalence and functional diversity of the antiretroviral restriction factor TRIMCyp in Macaca fascicularis.

Authors:  Elizabeth A Dietrich; Greg Brennan; Betsy Ferguson; Roger W Wiseman; David O'Connor; Shiu-Lok Hu
Journal:  J Virol       Date:  2011-07-27       Impact factor: 5.103

7.  The TRIM5 gene modulates penile mucosal acquisition of simian immunodeficiency virus in rhesus monkeys.

Authors:  Wendy W Yeh; Srinivas S Rao; So-Yon Lim; Jinrong Zhang; Peter T Hraber; Laura M Brassard; Corinne Luedemann; John Paul Todd; Alan Dodson; Ling Shen; Adam P Buzby; James B Whitney; Bette T Korber; Gary J Nabel; John R Mascola; Norman L Letvin
Journal:  J Virol       Date:  2011-07-20       Impact factor: 5.103

8.  Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine.

Authors:  Urvi M Parikh; Charles Dobard; Sunita Sharma; Mian-er Cong; Hongwei Jia; Amy Martin; Chou-Pong Pau; Debra L Hanson; Patricia Guenthner; James Smith; Ellen Kersh; J Gerardo Garcia-Lerma; Francis J Novembre; Ron Otten; Thomas Folks; Walid Heneine
Journal:  J Virol       Date:  2009-08-05       Impact factor: 5.103

9.  Preclinical assessment of HIV vaccines and microbicides by repeated low-dose virus challenges.

Authors:  Roland R Regoes; Ira M Longini; Mark B Feinberg; Silvija I Staprans
Journal:  PLoS Med       Date:  2005-07-19       Impact factor: 11.069

10.  Evolution of a TRIM5-CypA splice isoform in old world monkeys.

Authors:  Ruchi M Newman; Laura Hall; Andrea Kirmaier; Lu-Ann Pozzi; Erez Pery; Michael Farzan; Shawn P O'Neil; Welkin Johnson
Journal:  PLoS Pathog       Date:  2008-02-29       Impact factor: 6.823

View more
  5 in total

1.  Short communication: Viremic control is independent of repeated low-dose SHIVSF162p3 exposures.

Authors:  Tara R Henning; Debra Hanson; Sundaram A Vishwanathan; Katherine Butler; Charles Dobard; Gerardo Garcia-Lerma; Jessica Radzio; James Smith; Janet M McNicholl; Ellen N Kersh
Journal:  AIDS Res Hum Retroviruses       Date:  2014-10-14       Impact factor: 2.205

2.  Divergent HIV-1-Directed Immune Responses Generated by Systemic and Mucosal Immunization with Replicating Single-Cycle Adenoviruses in Rhesus Macaques.

Authors:  William E Matchett; Stephanie S Anguiano-Zarate; Pramod N Nehete; Kathryn Shelton; Bharti P Nehete; Guojun Yang; Stephanie Dorta-Estremera; Philip Barnette; Peng Xiao; Siddappa N Byrareddy; Francois Villinger; Ann J Hessell; Nancy L Haigwood; K Jagannadha Sastry; Michael A Barry
Journal:  J Virol       Date:  2019-05-01       Impact factor: 5.103

3.  Blocking HIV-1 Infection by Chromosomal Integrative Expression of Human CD4 on the Surface of Lactobacillus acidophilus ATCC 4356.

Authors:  Wenzhong Wei; Joshua Wiggins; Duoyi Hu; Vladimir Vrbanac; Dane Bowder; Michael Mellon; Andrew Tager; Joseph Sodroski; Shi-Hua Xiang
Journal:  J Virol       Date:  2019-04-03       Impact factor: 5.103

4.  Targeting α4β7 integrin reduces mucosal transmission of simian immunodeficiency virus and protects gut-associated lymphoid tissue from infection.

Authors:  Siddappa N Byrareddy; Brianne Kallam; James Arthos; Claudia Cicala; Fatima Nawaz; Joseph Hiatt; Ellen N Kersh; Janet M McNicholl; Debra Hanson; Keith A Reimann; Markus Brameier; Lutz Walter; Kenneth Rogers; Ann E Mayne; Paul Dunbar; Tara Villinger; Dawn Little; Tristram G Parslow; Philip J Santangelo; Francois Villinger; Anthony S Fauci; Aftab A Ansari
Journal:  Nat Med       Date:  2014-11-24       Impact factor: 53.440

5.  Development of a repeat-exposure penile SHIV infection model in macaques to evaluate biomedical preventions against HIV.

Authors:  David A Garber; James Mitchell; Debra Adams; Patricia Guenthner; Frank Deyounks; Shanon Ellis; Kristen Kelley; Ryan Johnson; Charles Dobard; Walid Heneine; Janet McNicholl
Journal:  PLoS One       Date:  2018-03-27       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.